Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
empasiprubart vs IVIg in multifocal motor neuropathy (empassion, Japan)
jRCT2061250020Phase 3Active, not recruiting
- Sponsor
- argenx
- Start
- Feb 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
01
Overview
Phase 3, randomised, double-blind trial of empasiprubart in multifocal motor neuropathy (MMN) (2 arms), sponsored by argenx. Primary endpoint: Primary efficacy endpoint. Started Feb 2026; status: active, not recruiting.
02
Drugs
empasiprubart
03
Conditions
multifocal motor neuropathy (MMN)
Beyond the preview
Go deeper on jRCT2061250020.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2061250020.